Recombinant therapeutic proteins: Production platforms and challenges
暂无分享,去创建一个
[1] A. C. Chang,et al. Construction of biologically functional bacterial plasmids in vitro. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Dell,et al. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. , 1987, The Journal of biological chemistry.
[3] R. B. Trimble,et al. Overview of N- and O-linked oligosaccharide structures found in various yeast species. , 1999, Biochimica et biophysica acta.
[4] K. Goa,et al. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[5] S. Urbinati,et al. [Bolus fibrinolytic therapy in acute myocardial infarction]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.
[6] A. Ghezzi,et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) , 2002, The Lancet.
[7] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[8] John B. Wong,et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C , 2003 .
[9] M. Manns,et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. , 2003, Gut.
[10] Teresa Mitchell,et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. , 2004, Glycobiology.
[11] G. Andria,et al. Therapeutic goals in the treatment of Gaucher disease. , 2004, Seminars in hematology.
[12] F. Schmidt,et al. Recombinant expression systems in the pharmaceutical industry , 2004, Applied Microbiology and Biotechnology.
[13] L. A. Palomares,et al. Production of recombinant proteins: challenges and solutions. , 2004, Methods in molecular biology.
[14] F. Saudek,et al. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] S. Elliott,et al. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. , 2005, Journal of pharmaceutical sciences.
[16] Key and Criteria to the Selection of An Expression Platform , 2005 .
[17] Huub Schellekens,et al. Factors influencing the immunogenicity of therapeutic proteins. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] S. Wildt,et al. The humanization of N-glycosylation pathways in yeast , 2005, Nature Reviews Microbiology.
[19] B. Rutkowski. Highlights of the epidemiology of renal replacement therapy in Central and Eastern Europe. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] M. Kuhlmann,et al. The protein science of biosimilars. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[21] W. Jiskoot,et al. Eprex-associated pure red cell aplasia and leachates , 2006, Nature Biotechnology.
[22] Huub Schellekens,et al. Immunogenicity of biopharmaceuticals. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] Guangxing Li,et al. Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. , 2007, Journal of biotechnology.
[24] Y. Eto,et al. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. , 2007, Molecular genetics and metabolism.
[25] S. M. Van Patten,et al. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. , 2007, Glycobiology.
[26] David S H Bell. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? , 2007, Drugs.
[27] Safety of erythropoiesis stimulating agents in patients on dialysis: current issues for nephrology nurses. , 2007, Nephrology nursing journal : journal of the American Nephrology Nurses' Association.